Smart Inhalers pose great potential in empowering disease management. Common difficulties faced by patients in the use of inhalers include inaccurate dosing, incorrect inhalation technique, insufficient deep inspiration flow rate and compliance. This technology aims to tackle the issue of over or underdosage delivery, device misuse and lack of monitoring or analytics found in current technologies. Using its proprietary precision dosing system, the device can accurately control dosages with an error rate of as low as 4% while enabling intelligent therapy monitoring and medical reporting for improved patient adherence and treatments.
The device functions by breath-activated operation to prevent wastage, heat-free fine particle liquid nebulization for safer drug delivery and deeper lung deposition. It features a propellant-free compact (pocket-sized) smart inhaler with liquid drug cartridges designed to replace injections and modernize inhaled therapies using the lung as a platform for delivery, addressing the lack of pain-free, hassle-free, smart alternatives for various medications. Due to its proprietary atomizer that works on almost 90% of most liquid medication, it has significant potential to be scaled in various drug types and markets, such as insulin, antivirals, hormones, and smart intranasal delivery for neurological conditions.
The technology owner is actively seeking collaboration opportunities with commercialization partners, pharmaceutical, biotech, OEM, CRO companies, who can license it to bring it to market or integrate it into existing healthcare systems. This scalability makes the technology highly appealing to a wide range of potential partners and licensees including co-development for customization and R&D or joint venture.
Industries where this technology can be deployed include:
Potential products based on this technology include:
The approximate market size for this smart inhaler technology can be substantial, given its potential applicability across various therapeutic areas. The global inhaler market was valued at around US$39.3 Billion in 2022 while the diabetes management market US$92.97 Billion. Considering the smart inhaler's ability to address both the pulmonary drug delivery and daily injection markets, the Total Available Market can be up to a US$1 Trillion adding up all the therapeutic areas.
This proprietary smart inhaler technology represents a significant improvement over the current "State-of-the-Art" in drug delivery systems. Its unique value lies in its combination of precision dosing, versatility, and improved patient experience.
Benefits for healthcare professionals and patients include:
Benefits for partners: